Intervention

QL1706

ClinicalTrials.gov intervention label

Clinical trials10

Recruiting4

Common conditions12

Lead sponsors shown7

Clinical trials

10 shown

Iparomlimab and Tuvonralimab (QL1706) in Patients With HR-positive, HER2-negative Advanced Breast CancerNCT07180160 · 2025-09-25

QL1706 for the Neoadjuvant Treatment of HR+/HER2- Breast CancerNCT06967103 · 2025-09-08

Perioperative Study of Iparomlimab and Tuvonralimab in Resectable NSCLCNCT06897046 · 2025-07-30

QL1706 Plus Chemotherapy +/- Bevacizumab in 1L Treatment of R/mTNBCNCT06786026 · 2024-10-09

QL1706 Plus Anlotinib as a Later-line Treatment for Patients With Advanced Lung CancerNCT07636226 · 2026-07-30

NOT_YET_RECRUITING

Phase 2 Clinical Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Platinum Chemotherapy Versus Platinum Chemotherapy in the Treatment of Second-/Third-line Triple Negative Breast Cancer (TNBC)NCT07413601 · 2026-02-10

NOT_YET_RECRUITING

A Study of QL1706 in Combination With Chemotherapy in PD-L1-Negative Non-small Cell Lung CancerNCT05690945 · 2023-02-15

ACTIVE_NOT_RECRUITING

A Phase II Study of CRT Combined With QL1706 in ESCC PatientsNCT05490719 · 2022-08-01

A Study of QL1706 Combined With Chemotherapy in Advanced Non-small Cell Lung CancerNCT05329025 · 2022-06-01

Safety and Efficacy Study of First-line Treatment With QL1706 Plus Chemotherapy in Extensive-Stage Small Cell Lung CancerNCT05309629 · 2022-04-18

Common conditions

Advanced Breast Cancer1 Breast Cancer1 Esophageal Squamous Cell Carcinoma1 Extensive-stage Small-cell Lung Cancer1 HR+/HER2- Breast Cancer1 II-IIIB1 Lung Cancer1 Non-small Cell Lung Cancer (NSCLC)1 Non-small-cell Lung Cancer1 Small Cell Lung Cancer1 TNBC, Triple Negative Breast Cancer1 Triple Negative Breast Cancer Metastatic1

Leading sponsors

Qilu Pharmaceutical Co., Ltd.3 Cancer Institute and Hospital, Chinese Academy of Medical Sciences2 Fudan University1 Henan Cancer Hospital1 Sun Yat-sen University1 Tianjin Medical University Cancer Institute and Hospital1 Wenjin Yin1

Trial status mix

RECRUITING4

NOT_YET_RECRUITING2

UNKNOWN2

ACTIVE_NOT_RECRUITING1

COMPLETED1

Phase mix

PHASE29

PHASE32

How to interpret this record

CureCurrent links normalized diseases, medicines, registry study labels, sponsors and research sites. A link is not the same as a finding of clinical effectiveness. Our research guides explain how to compare studies, decode RxNorm identities, and avoid over-interpreting site and trial counts. See the published database coverage for mapping completeness.

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.